Overview

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, single-dose, 2-way crossover PK comparability study of CB-839 administered as capsule and tablet formulations in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Calithera Biosciences, Inc